how to grow a vegetable

Suramin is a 100-year-old drug developed to treat African sleeping sickness. It is not approved for any therapeutic use in the U.S. However, a small clinical trial at UC San Diego School of Medicine found that a single intravenous dose of suramin produced measurable, but transient, improvements in five boys with autism spectrum disorder (ASD). More broadly, the trial findings support the “cell danger response theory,” which posits that autism is driven by metabolic dysfunction — and thus treatable. Larger, longer clinical trials are needed to assess suramin as an ASD treatment. In this video we hear from lead researcher Robert Naviaux, MD, PhD, and the mothers of two boys who received suramin in the trial. For more, visit http://health.ucsd.edu/suramin

A small, randomized clinical trial at UC San Diego School of Medicine found that a single intravenous dose of a century-old drug called suramin produced measurable, but transient, improvement of core symptoms of autism spectrum disorder (ASD). But more broadly, the trial findings support the “Cell Danger Response theory,” which posits that autism and other chronic conditions are fundamentally driven by metabolic dysfunction—and thus treatable. This whiteboard animation explains Cell Danger Response in autistic neurons before and after suramin treatment.